Bioindustry Park and biopmed
|
|
|
- Neil Curtis
- 10 years ago
- Views:
Transcription
1 Bioindustry Park and biopmed Fabrizio Conicella / 1
2 CONTENTS Piemonte cluster and Bioindustry Park Silvano Fumero biopmed cluster initiative biopmed internationalisation strategy Cluster delivering values to companies BioXcluster / 2
3 ITALY: PIEMONTE REGION Ø 2.2 billion R&D investments Ø 1,000 R&D contracts Ø 220 R&D centers, 380 Labs Ø 6 Science & Technology Parks Ø 4 Universities Verbania Ø 4.4 M inhabitants Ø billion GDP Ø 38.5 billion export Ø 467,500 companies Biella Novara 1 st region in Italy for: Ø Private R&D investment Ø Hi-tech patents Torino Cuneo Asti Vercelli Alessandria Ø Strong relationships with other European Regions / 3
4 BIOINDUSTRY PARK SILVANO FUMERO Ø Science Park focused on life sciences, created with the support of Regione Piemonte in the EU programs framework (beginning 90 s) Operational since Ø It hosts more than 30 organizations Ø Managing company of the Innovation Cluster biopmed Ø Member of national and international networks Offer sqm labs, office spaces R&D shared facilities R&D scientific services (Able Biosciences initiatives) 1 incubator Consultancy in biomanagement Conference centre Bioindustry Park 2013 All Rights Reserved / 4
5 BIOINDUSTRY PARK SILVANO FUMERO AS A COMPANY ü Private company (limited company) with public majority ü 27 full time employees + around 10 project based contracts ü Around 5 Ml euro turnover Total assets 23 Ml euro (2012) ü Positive EBITDA and EBIT; / 5
6 BIOINDUSTRY PARK: A PLATFORM FOR COMPANY DEVELOPMENT General services for lessees Incubation and start-up R&D: exploitation of scientific results and scientific services Cluster development, TT and International projects / 6
7 BIOINDUSTRY PARK SILVANO FUMERO HOSTING ACTIVITIES Space and equipment Support for the access to public grants Management and IP support Training Congress Centre Complete package of services to facilitate start-up and company spin off at each development phase: Pre start-up support Start-up assistance Development assistance Way-out support / 7
8 BIOINDUSTRY PARK: HOSTED ORGANISATIONS NatiMab Bioindustry Park 2013 All Rights Reserved / 8
9 BIOINDUSTRY PARK SILVANO FUMERO: SCIENTIFC ACTIVITIES ü Scien=fic support and shared facili=es ü Tools for scien=fic results exploita=on ü Technology Transfer ü Added value scien=fic services ü GLP/GMP facili=es ü Partnership with Università di Torino (Imaging and chemistry) and CNR (proteomics) Bioindustry Park 2013 All Rights Reserved / 9
10 ABLE BIOSCIENCES: SCIENTIFIC SERVICE PROVIDER Discovery Preclinical development Target, MOA, POC, Phase I Phase II Phase III Phase IV Regulatory/development requirements SUPPORT FOR DRUG DISCOVERY & DEVELOPMENT Target validation, drug activity, MOA, POC e-admet studies Biomarker discovery and detection Custom synthesis Spin-off, start-up, SMEs Pharma / Biotech To reach faster the POC and to boost licensing opportunities Tools Customized cell-based assays Protein profiling - MALDI imaging Mass spectrometry LC-MS/MS Gene expression qpcr Immunoassays CRO ACTIVITIES ADMET studies Bioanalytical methods for drugs and biomarkers. Clinical stage companies To fulfil all Your regulatory and development requirements / 10
11 BIOINDUSTRY PARK SILVANO FUMERO: A SYSTEM TO SPEED UP PRODUCT DEVELOPMENT Research Preclinical Clinical Bioanaly1cs Biomarkers Cell & Mol. Toxicology Custom synthesis Bioanaly1cs Biomarkers Cell & Mol. Toxicology Bioanaly1cs Biomarkers Stem cells Cell & Mol Biology GMP Stem cells Compounds Labelling Injectable GMP Stem cells Compounds Labelling Injectable In vivo in rodents Preliminary PK Preliminary Tox In vivo in rodents PK Pharmacology Preclinical Imaging More of 50 different clients in the last 4 years.. / 11
12 Start- up creation: the «Discovery approach» Public funds Scientific results PPP Public-Private Partnership Seed/start-up money Business angels Infrastructures, general services, addedd value services,, business development Financing, networking and skills Venture Capitalists network Technology Transfer through start-up creation / 12
13 BIOINDUSTRY PARK SILVANO FUMERO: main results Opening of Bioindustry Park Year zero (1999) 2013 data confirms 2011 data / 13
14 BIOINDUSTRY PARK: A PLATFORM FOR COMPANY DEVELOPMENT General services for lessees Incubation and start-up R&D: exploitation of scientific results and scientific services Cluster development, TT and International projects / 14
15 Ø A EU world class cluster dedicated to bio and medical technologies created in 2009 Ø First Italian cluster for performances (MEDALICS/POLICS 2012) Ø A core founder of the ALISEI (Advanced LIfe SciEnces in Italy) national cluster that involves 13 different actors Ø A shared smart approach to innovation: converging technologies Overlapping different technological knowledge to reach innovative solutions to ensure a better future Synergies with local clusters (ICT, New materials, textiles...), with EP and non EP clusters 200 health care 132 R&D centers 3924 scientists Companies, Universities, R&D centers, foundations BIOPMED CLUSTER INITIATIVE National & International Hubs 370+ ENLARGE COMMUNITY 80+ CORE MEMBERS The biopmed Community / 15
16 SMEs INTERNATIONALISATION AND THE CLUSTER ENVIRONMENT: BIOPMED APPROACH Governance Labeling Project building Working groups Community building Shared access to infrastructures (material / immaterial) R&D Projects Added value shared services Regional financing International networking International clusters Events organisation and participation, information, opportunities and support to single companies, universities and agencies in sectorial internationalisation Council of European Bioregions International projects International agreements Soft landing agreements / 16
17 THE CLUSTER ENVIRONMENT Clear Goal setting Local Mapping (scientific assets, market focus, technology used by companies, etc) Promotional material and smart participation to events Personal/organisational network Training/skills Marketing approach Strategy definition and sharing KPI/outputs Bioindustry Park 2013 All Rights Reserved / 17
18 BIOPMED: PERFORMANCES Companies contacted and involved 350 Scientist contacted and involved 3500 Organizations formally and contractually linked Total output project building activities Technical work-shops organized 34 Companies involved in internationalisation and international activities 147 Advanced services financed 15 Feasibility studies and R&D projects financed EU funded project ongoing and presented % of members involved in projects (cumulative) Overall value of initiatives linked to cluster activities Involvement in institutional advisory board external to the region % Ø biopmed obtained the Bronze label by the European Secretariat for cluster Analysis Ø biopmed ranked 1 st in a national evaluation of clusters and science park related to performances Source: Dai distretti industriali ai poli di innovazione. L'Italia nel Mediterraneo, M. Ferarra, R. Mavilia EGEA, 2012 / 18
19 Genomics, Biochemistry, Molecular & cellular biology Diagnos1c & Theranos1cs Electronical, medical & laboratory equipment Medical biomaterials Medical technology & Biomedical engineering Func1onal food Microbiological consor1a Computer sciences Disease Preven1on ROTARIC ATHIMAG SAFE TAN SUN TAN PREVI IaRO; ROTARIC Nutratec; NutraPiem P- Arap; RiOrTec For1Lat; P- Claim P- Oryza; Donkeymilk Resican; SuJTe Nogluterbug MicoDiaBreast ARAS BACOSTE SafeNutrifood Prothesis, biomedical Devices/ instrumenta1on & drug delivery BIOBONE CARDIOMITRAL SWAP SiNplant Self exp. DES TINET; I.B.G. IPEEI BONEJECT KEME; BIOMAG PIEDMONT Dense- gas CRYO CRYOPHARMA NANOSTENT FIDIS BIOMICROFAB DESTINI; BIOMAG WILOP; JIGTO FACE; ORECO HEXEC NeuroVirtual3D Nuvola3D RICCAmente Regenera1ve Medicine MOSQUITO HYPERSPECTRA STELLA BICONerve TINET; I.B.G. QUANTADIPO BONEJECT PIEDMONT PLA scaffolds NanoStem B.B.S. FACE WEB BI Pharmaceu1cal TAB2 NOVADEP TLR7A; ERP NATIMAB ATHEROVAX PSSEIK Personalized Medicine MOSQUITO GNRs Pred_HEALTH FaPre P- MOSP Diagnos1c EPIgene1c screening NuGeSa FAST Beta- agonist detec1on DMS; Bioprotech ATHIMAG HYPERSPECTRA; STELLA; LOCHTECH MicroDiBi PROMOTECO BANP. TrCD; Idata E_LAB; FAST P- MOSP ) Veterinary FLUOMAG CANESTRO
20 SMEs INTERNATIONALISATION AND THE CLUSTER ENVIRONMENT: BIOPMED STRATEGY International positioning Learning and working with others Matching with peers Corporate positioning for FDI and reputation Segmentation of countries following market trends, mapping of local assets and synergies Working with the best clusters to learn and growth not to raise money Identification of complementary clusters (dimension, stage of growth, technical assets, etc) Sharing/selling know-how Consultancy/Transfer of know-how to potential/future partners/clients Delivering value for companies creating a platform for growth Quality as a KPI. Not interested in numbers but in be able to deliver added value to specific companies: possibility to evaluate results. Working with partners (local/ international) / 20
21 BIOPMED: INTERNATIONAL NETWORK AND PROJECTS FR: Lyonbiopole; ADEBAG; Eurobiomed; Genopole; I-Care DE: BioM; Technologiepark Heidelberg, biotop PL: Wrocław Center for S&T in Medicine ES: BioCAT; Parque Tecnologico di Vizkaia, BioCat IT: Toscana Life Sciences CH: BioAlps ; DK: MVA UK: One Nucleus; SWE: Stockolm Science City BioCulture Biolake, Biobay, Juke, ZhangJiang Scientific Park Technology Centre of New Jersey CBS FIPASE BioRio (ongoing) Israel BioNegev cluster; RAD FABA Federation of Asian Biotech Associations STC Bioindustry Park 2013 All Rights Reserved / 21
22 CLUSTER INTERNATIONALISATION THROUGH A PARTNERSHIP BASED APPROACH To develop a common and joint internationalisation strategy for the 4 Life Sciences Clusters to reinforce European SMEs competitiveness beyond Europe Mutualising and sharing internationalisation tools (programs, practices, networks) already implemented to obtain economy of scale/knowledge Identifying the most efficient tools for SMEs competitiveness on the global market Testing common pilot actions towards 3 targeted markets: Brazil, China, United States Reinforcing the visibility of the 4 European Life Sciences Clusters together and European competences worldwide ERAI (Rhône-Alpes, FR) Project Leader Lyonbiopole (Rhône-Alpes, FR) Host Cluster BioCat (Catalonia, SP) Invited Cluster BioM (Bayern Region, DE) Invited Cluster BioPmed (Piedmont, IT) Invited Cluster / 22
23 BIOPMED AND INTERNATIONALISATION STRATEGIES: WHAT WE ARE LOOKING FOR, WHAT WE ARE OFFERING...? Ø Companies interested in developing their activities in Italy: technology scouting, soft landing, R&D, scientific services, managerial consulting, investments, etc Ø Incubators, science parks and clusters interested in developing win-win approaches to support in a reciprocal way our companies Ø Science parks, incubators and companies interested in our know how Ø Investors (Seed, corporate funds and VCs) to develop innovative way to finance high growth start-ups Ø Universities and R&D centers interested in exploiting their knowledge in our cluster / 23
24 BIO-EUROPE SPRING 2014 BIO-Europe Spring will be organised in Turin (Piemonte) March 10 12, / 24
25 Is the team that win not the single player..! Bioindustry Park Silvano Fumero S.p.A. Fabrizio Conicella Director Business Development and Interna1onal projects Via Ribes, Collerefo Giacosa (TO) Italy Tel Fax [email protected]
Università di Padova (IT) Dept. of Industrial Engineering Date: from - to (month/year) September 2012. Innovation Marks: N.A.
1. FAMILY NAME: Conicella 2. FIRST NAMES: Fabrizio 3. DATE OF BIRTH: 12/15/1965 4. NATIONALITY: Italian 5. CIVIL STATUS: Single CURRICULUM VITAE 6. ADDRESS: C/O BIOINDUSTRY PARK SILVANO FUMERO SPA Via
Eudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
Promoting hi-tech entrepreneurship through university -based technology incubatorssome thoughts coming from experience
Trade and Development Board Investment, Enterprise and Development Commission Multi-year expert meeting on enterprise development policies and capacity-building in science, technology and innovation Geneva,
Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
The Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
How To Promote Agricultural Productivity And Sustainability
La E.I.P. «Agricultural Productivity and Sustainability: il coinvolgimento delle imprese chimiche PARCO TECNOLOGICO PADANO Simona Palermo - Project Manager Lodi innovation Cluster Parco Tecnologico Padano
Santaravalley: Integrating scientific research, high-tech business and academia Prof. Vladas Algirdas Bumelis President of Santara valley Association Vilnius, Lithuania 2013July 18 th Santara Valley Association
Valentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
SIPBS Portfolio. 2012-13 Entry
SIPBS Portfolio 2012-13 Entry MSc Programmes Existing: MSc Pharmaceutical Analysis MSc Analysis of Medicines (distance learning) MSc Clinical Pharmacy New Programmes just launched for Sept 2012 entry:
1_ The Italian Startup Ecosystem: "Who s Who" 2_ Investments in hi-tech startups in Italy. 3_ A selection of significant startups
1_ The Italian Startup Ecosystem: "Who s Who" 2_ Investments in hi-tech startups in Italy 3_ A selection of significant startups The Italian Startup Ecosystem The players Funded Startups Innovative Startups
Alain Schmitt Directorate General for Enterprise October 14 th, 2014
Alain Schmitt Directorate General for Enterprise October 14 th, 2014 I. Facts and figures about innovation in France II. Startup financing III. Entrepreneurship culture and ecosystems Worldwide ranking
SME support under Horizon 2020 how to make it work
SME support under Horizon 2020 how to make it work Olivier Brunet Unit Regional dimension of innovation Directorate General Research &Innovation European Commission The Multiannual Financial Framework
DMPK: Experimentation & Data
DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students
University of Medicine and Dentistry of New Jersey (UMDNJ)
University of Medicine and Dentistry of New Jersey (UMDNJ) Dual-Degree Program between the UMDNJ Graduate School of Biomedical Sciences (GSBS) And the UMDNJ School of Public Health (SPH) Leading to the:
Bridging Innovation and Business
Otaniemi Incubation Excellence Bridging Innovation and Business Pertti Vuorela, Technopolis Ventures Ltd. Networking Model in Business exploitation Otaniemi High-Tech Area Academic & Research Partners
ASSOBIOMEDICA AND BIOMEDICAL START-UPS. Vera Codazzi, Ph.D.
ASSOBIOMEDICA AND BIOMEDICAL START-UPS Vera Codazzi, Ph.D. Startup Biomed FORUM Torino, 26-27 febbraio 2015 2 Towards innovation in the medical device sector NANO-TECHNOLOGIES CHEMISTRY ELECTRONICS MATERIALS
ELEFTHO : Supporting Business Incubators & technology parks.
ELEFTHO : Supporting Business Incubators & technology parks. Region of Central Macedonia Task Page 1 of 14 Contents Description of policy... 3 Name of the policy... 3 Responsible body... 3 Implementation
Michele Genovese DG Research and Innovation Specific International Cooperation Activities
Michele Genovese DG Research and Innovation Specific International Cooperation Activities 1 2 1. Innovation in a changing, challenging world New Priorities 3 Recent changes in the global economic system
Project Management. Dissemination and Exploitation Services in Horizon 2020
Project Management Dissemination and Exploitation Services in Horizon 2020 Ontwerp: Studio Edwin de Boer 2 Project Management Dissemination and Exploitation Services in Horizon 2020 ttopstart - Project
M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics
of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted
Milan: a rich region Province of Milan = 3.7 million inhabitants Italy s richest urban agglomeration & one of the wealthy OECD metro regions
The case of Milan Milan: a rich region Province of Milan = 3.7 million inhabitants Italy s richest urban agglomeration & one of the wealthy OECD metro regions 35 34.08 Milan Province 33 31 Highest GDP
THE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
Master of Science in Biomedical Sciences
Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving
An Introduction to Genomics and SAS Scientific Discovery Solutions
An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!
Molecular Biotechnology Master s Degree Program
> APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one
Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science
CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The
Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles
ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES
THE ITALIAN POLICY FOR INNOVATIVE ENTREPRENEURSHIP @CORBETTAMATTIA ITALIAN MINISTRY OF ECONOMIC DEVELOPMENT MINISTER S TECHNICAL SECRETARIAT INNOVATIVE STARTUP ESTABLISHED FOR NO LONGER THAN 60 MONTHS
The National Centre for Biomedical Engineering Science
The How this Integrated Technology Platform has impacted the development of R&D Clusters in Galway Jacinta Thornton, PhD Executive Manager, NCBES National Centre for Biomedical Engineering g Science Mission
Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
How To Create A Successful Economy
INTERNATIONAL IMP³ROVE ROUNDTABLE: FOSTERING COHESION WITH INNOVATION Düsseldorf, 25 November 2015 Christian SAUBLENS IN EUROPE, THE EU COMMISSION PROMOTES THE CONCEPT OF RESEARCH AND INNOVATION STRATEGIES
9360/15 FMA/AFG/cb 1 DG G 3 C
Council of the European Union Brussels, 29 May 2015 (OR. en) 9360/15 OUTCOME OF PROCEEDINGS From: To: Council Delegations RECH 183 TELECOM 134 COMPET 288 IND 92 No. prev. doc.: 8970/15 RECH 141 TELECOM
8970/15 FMA/AFG/cb 1 DG G 3 C
Council of the European Union Brussels, 19 May 2015 (OR. en) 8970/15 NOTE RECH 141 TELECOM 119 COMPET 228 IND 80 From: Permanent Representatives Committee (Part 1) To: Council No. prev. doc.: 8583/15 RECH
Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -
A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,
BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover
The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge
Join our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
BIOSCIENCES COURSE TITLE AWARD
COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,
BS in Pharmaceutical Science (BSPS) degree program University of Rhode Island
To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,
Nanomedicine in Horizon 2020
Nanomedicine in Horizon 2020 Heico FRIMA Programme Officer European Commission Directorate-General for Research & Directorate D: Key Enabling Technologies [email protected] ETPN Annual Event 2014
Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis
Oncoxx Biotech Saverio Alberti Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis INTRODUCTION Oncoxx Biotech S.r.l. is a Cancer Biotech Company as partnership between Chieti University
BioTalentum Ltd. Hungary Prof. András Dinnyés Director
BioTalentum Ltd. Hungary Prof. András Dinnyés Director Foto a cég épületéről Novel Transgenic Animal Models, Cellular Models and Stem Cell Systems for Biomedical Research and Drug Testing Fourth EUA CDE
InnoEnterprise Project Declan Gordon Carroll
InnoEnterprise Project Declan Gordon Carroll InnoEnterprise Project Support to knowledge based and innovative enterprises and technology transfer to business in Ukraine 1.Organising a conduit structure
Dalla Ricerca all Impresa le Start up di IIT. Lorenzo De Michieli, Ph.D. Technology Transfer - Manager [email protected]
Dalla Ricerca all Impresa le Start up di IIT Lorenzo De Michieli, Ph.D. Technology Transfer - Manager [email protected] Istituto Italiano di Tecnologia promotes excellence in fundamental and applied
Harald Isemann. Vienna Brno Olomouc. Research Institute for Molecular Pathology
Harald Isemann Vienna Brno Olomouc Managing Director Research Institute for Molecular Pathology The Campus The Campus Max F. Perutz Laboratories www.mfpl.ac.at www.univie.ac.at www.meduniwien.ac.at Research
Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics
Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics John D Antonio Practice Leader, Licensing & Competitive Intelligence About Paragon We help increase asset value from
How To Get A Grant From Kinesis
- The collaboration initiative to move drug candidates forward Introduction What are we offering? How? Why apply? Terms Background For grant applications and to attract venture capital start-up companies
MSc in Toxicology. Master Degree Programme
Master Degree Programme MSc in Toxicology Department of Pharmaceutical Sciences, University of Basel Swiss Centre for Applied Human Toxicology (SCAHT) Master of Science in Toxicology University of Basel
Agenda. 2. How does it work? International network for Market assessment -> Mapping > R2B B2B I2B opportunities detection -> Match making events
Agenda 1. TEXTECH Med a textile international network for competitiveness 2. How does it work? International network for Market assessment -> Mapping > R2B B2B I2B opportunities detection -> Match making
College of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016
College of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016 Degrees Offered Doctor of Philosophy in Experimental Therapeutics Doctor of Philosophy in Medicinal Chemistry Master of Science
EIT: a new approach to innovation in European innovation or created by us to be solved by us
EIT: a new approach to innovation in European innovation or created by us to be solved by us Prof. Anders Flodström EIT Vice-Chairman WIPO EIT-Investing in the Grand Opportunities Geneva, July 11 and 12.
Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research
Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from
Chapter 6. Financing of innovative entrepreneurs
Chapter 6. Financing of innovative entrepreneurs Ukraine has entrepreneurial talent and a relatively strong risk-taking attitude. These are major ingredients for any policy intervention seeking to promote
Making the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
THE ITALIAN STARTUP AGENDA
THE ITALIAN STARTUP AGENDA POLICIES AND STRATEGIES FOR STARTUPS STEFANO FIRPO ITALIAN MINISTRY OF ECONOMIC DEVELOPMENT, HEAD OF THE MINISTER S TECHNICAL SECRETARIAT LAST UPDATE: 10 FEBRUARY 2015 #RESTARTITALIA
Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
Report from the visiting commitee
Section des Unités de recherche Report from the visiting commitee Research unit: Biothérapies hépatiques University of Nantes January 2008 Section des Unités de recherche Report from the visiting committee
BIOTECHNOLOGY. about biotechnology
BIOTECHNOLOGY about biotechnology Introduction Biotechnology from humble beginnings based on fermentation processes used to make foods, alcoholic drinks, antibiotics and more recently, speciality chemicals
European Molecular Biology Laboratory Case Example
European Molecular Biology Laboratory Case Example Dr. Silke Schumacher Director International Relations EMBL Member States Austria 1974 Denmark 1974 France 1974 Germany 1974 Israel 1974 Italy 1974 Netherlands
GlycArt Biotechnology AG From Inception to trade sale and what happened after...
GlycArt Biotechnology AG From Inception to trade sale and what happened after... Dr. Joël Jean-Mairet From the Idea to Spin-off from the Swiss Federal Institute of Technology 1996 At the midst his PhD
We use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
MSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary
MSc program Peter Heegaard, Head of Studies DTU Veterinary There is a need for Pharma graduates Pharma industry in its widest sense (see next slide) Research institutions (public and private) Consultants
Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form
C H I Cambridge Healthtech Institute s Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form Over 800,000 names segmented by scientific interest Featuring U.S and International
Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many
1) SCOPE OF THE PROGRAM
CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany
Executive summary of the new Italian legislation on start-ups
Executive summary of the new Italian legislation on start-ups 29 th January 2014 Italian Ministry of Economic Development Minister s Technical Secretariat The steps Italy has taken in order to become the
STRENGTHENING NATIONAL SYSTEMS OF INNOVATION: THE IMPORTANCE OF NATIONAL COLLABORATION, INCUBATORS, ENTREPRENEURSHIP AND NICHE MANAGEMENT
STRENGTHENING NATIONAL SYSTEMS OF INNOVATION: THE IMPORTANCE OF NATIONAL COLLABORATION, INCUBATORS, ENTREPRENEURSHIP AND NICHE MANAGEMENT UNFCCC Workshop on National Systems of Innovation and Climate Technology
Financing innovation. Operational Programme Enterprise and Innovation for Competitiveness 2014-2020: Ing. Marcela Příhodová EU Funds Section, MIT
Operational Programme Enterprise and Innovation for Competitiveness 2014-2020: Financing innovation Ing. Marcela Příhodová EU Funds Section, MIT 19. května 2014, Ostrava 14 October 2014, Prague Operational
October 17, 2005. Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892
October 17, 2005 Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892 Dear Dr. Zerhouni: The undersigned nonprofit medical and scientific societies
exactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
I TECH-OFF INFORMATION TECHNOLOGY SPIN-OFF. Giulio Giunti P. 1. Giulio Giunti, 5th February 2008
I TECH-OFF INFORMATION TECHNOLOGY SPIN-OFF Giulio Giunti P. 1 Contents Definition of incubator & incubation General information on I TECH-OFF Phases and selection process Services Candidate identikit Results
NUVISAN Pharma Services
NUVISAN Pharma Services CESI MS Now available! 1st CRO in Europe! At the highest levels of quality. LABORATORY SERVICES Equipment update STATE OF THE ART AT NUVISAN CESI MS Now available! 1st CRO in Europe!
Spinnovator Public Private Partnership for Spin-offs
A project of Ascenion and Vesalius Biocapital supported by the BMBF 5th International VPM Days Hannover Spinnovator Public Private Partnership for Spin-offs Christian Stein, September 1, 2011 Ascenion
Presented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
STRATEGY OF OPEN JOINT-STOCK COMPANY RUSNANO UNTIL 2020
Appendix 1 to protocol APPROVED by the Board of Directors of Open Joint Stock Company RUSNANO Protocol from 20 December 2013 #27 (section I) STRATEGY OF OPEN JOINT-STOCK COMPANY RUSNANO UNTIL 2020 Moscow
